Is Higher Binding Capacity Always Better When Selecting Protein A Resins?

May 09,2026

Bestchrom

In antibody purification, affinity chromatography is almost always the first step in the process.

When selecting affinity resins, “binding capacity” is usually the first parameter people mention — and the one most easily overemphasized:

“This resin delivers a DBC of 60 g/L.”

“That one is even higher.”

It sounds attractive and straightforward.

However, in real industrial processes, is higher binding capacity always better?

The answer is simple: Not necessarily. In many cases, the answer is even actually NO.

Why is “high binding capacity” always emphasized?

Dynamic Binding Capacity (DBC) is, of course, an important parameter. It directly determines:

•  how much antibody a column can load

•  how much material can be processed in a single cycle

•  whether larger column are required

With high-titer upstream processes routinely reaching 5–10 g/L or more, the pressure on downstream capacity has intensified. If the resin can’t keep up,  larger columns or more cycles have to be adapted.

That’s why high capacity has become one of the brightest selling points in resin marketing.

However, the issue is that binding capacity is just a single consideration, whereas in the real world industrial manufacturing is a systemic project.

Binding capacity and flow rate often trade off against each other

At the engineering level, there is a very practical trade-off: in many cases, higher binding capacity is achieved at the cost of slower operation.

To achieve higher capacity, resins often require:

•  higher ligand density

•  more complex and deeper pore structures

This leads to a direct consequence: increased mass transfer resistance. In other words, if the flow rate is not slow enough:

•  proteins do not have sufficient time to diffuse into the pores

•  the claimed high binding capacity cannot be fully realized

As a result, high-capacity resins frequently require:

• longer residence times

• lower flow rates

• significantly longer cycle times

In contrast, resins with more moderate binding capacity can often deliver higher overall productivity. The reasons are as follows:

•  better bead rigidity

•  pore structure more favorable for fast mass transfer

•  ability to operate at higher linear velocity and greater bed height

Therefore, if higher binding capacity comes at the expense of flow rate and cycle time, it may not be cost-effective.

Binding capacity must be matched  upstream expression levels

Another frequently overlooked question is whether the binding capacity can actually be fully utilized.

◉ Low or moderate expression levels

If the upstream titer is not high (e.g., <2–3 g/L), fully loading a high-capacity affinity column would mean:

•  extremely long loading times

•  prolonged holding time at room temperature or under cold conditions for the harvest material

This is not only an efficiency issue, but also a risk factor. In such cases, the cost paid for “high capacity” is not translated into real process value.

◉ High expression levels

When upstream titers are already high (>5 g/L), high-capacity resins begin to show their true advantages by reducing column volume or the number of cycles and alleviating downstream bottlenecks.

Binding capacity is not about being the higher the better., but about being properly matched  upstream expression levels.

Higher binding capacity does not necessarily mean better selectivity

This is a point that is rarely mentioned in marketing, but very real in process development. When a resin operates at its capacity limit, the followings may occur:

•  antibodies become highly crowded within the pores

•  impurities (HCP, DNA, aggregates) may be physically trapped

•  washing becomes less effective

As a result:

•  the apparent binding capacity is high

•  but eluate purity decreases

•  downstream steps (viral inactivation, filtration) face increased burden

In addition, extremely high binding capacity often leads to very high elution concentrations:

•  elution buffer may reach 50–80 mg/mL

•  viscosity increases

•  aggregation risk rises

If higher capacity results in lower purity, increased risk, and greater downstream difficulty, then such capacity is essentially “overstated” from a process perspective.

Binding capacity and lifetime are two sides of the same coin.

One issue that cannot be ignored is that resins are not used once or twice — they are expected to last for many years and hundreds of cycles.

To acheive extreme binding capacity, some resins may:

•  adopt more aggressive ligand coupling strategies

•  be subjected to greater chemical and mechanical stress at the structural level

Under repeated NaOH cleaning (CIP), this may result in:

•  faster ligand degradation

•  more rapid loss of capacity over time

•  shortened resin lifetime

In industrial production, any reduction in lifetime will ultimately be reflected in the cost of goods (CoG).

A More Practical Approach to Resin Selection

In real industrial resin selection, binding capacity should be evaluated within a broader context:

•  What is the usable binding capacity at the target flow rate and bed height?

•  What is the productivity (g/L/h) at the target number of cycles?

Under defined CIP conditions, how many cycles can be run consistently?

•  Does it reduce overall process complexity?

•  Within this framework, the role of binding capacity becomes clear: it is a threshold, not the end goal.

Once binding capacity reaches a “sufficient” level, an additional 3–5 g/L is often less valuable than:

•  higher flow rates

•  more stable lifetime

•  a more robust overall process window

Conclusion

Pursuing high binding capacity is not wrong in itself. The real question is whether it is applied in the right way and in the right process.

In antibody affinity resin selection, a mature decision is not about which resin has the highest capacity, but which one can best balance capacity, speed, stability, and lifetime under real process conditions.

This is what truly matters from an industrial perspective.